Future perspectives for acute promyelocytic leukemia therapy

Seminars in Hematology

Volumn 38, Issue 1, 2001, Pages 86-91

  Cassinat, Bruno ^a   Chomienne, Christine ^a  

^a SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

RETINOIC ACID;

ACUTE MYELOBLASTIC LEUKEMIA; ARTICLE; BONE MARROW CELL; CANCER SURVIVAL; CELL CYCLE; CELL DIFFERENTIATION; CELL SPECIFICITY; CELL SURVIVAL; LEUKEMOGENESIS; PRIORITY JOURNAL; TREATMENT PLANNING;

EID: 0035140060     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0037-1963(01)90008-3     Document Type: Article

References (31)

1. All-trans retinoic acid pharmacokinetics and bioavailability in acute promyelocytic leukemia: Intracellular concentrations and biologic response relationship
2. Terminal differentiation of human promyelocytic leukemia cells in primary culture in response to retinoic acid
3. Combination of ATRA with G-CSF or RARA agonists enhances differentiation induction of fresh APL cells
4. Ligation of the CD44 adhesion molecule reverses blockage of differentiation in human acute myeloid leukemia
5. Retinoic acid and interferon signaling cross-talk in normal and RA. resistant APL cells
6. Low dose chemotherapy and differentiating agents
7. All-trans retinoic acid in acute promyelocytic leukemia II. In vitro studies: Structure-function relationship
8. Retinoid acid differentiation therapy in promyelocytic leukemia
9. Functional G-CSF pathways in t(8;21) leukemic cells allow for differentiation induction and degradation of AML1-ETO
10. Resistance to all-trans retinoic acid therapy in relapsing acute promyelocytic leukemia
11. Modulation of IL-8, IL-1 beta and G-CSF secretion by all-trans retinoic acid in acute promyelocytic leukemia
12. Molecular remission induced by liposomal-encapsulated all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia
13. A randomized comparison of all trans retinoic acid followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia
14. Complete remission in acute myeloid leukaemia with t(8;21) following treatment with G-CSF: Flow cytometric analysis of in vivo and in vitro effects on cell maturation
15. Acute promy-elocytic leukemia a model for cross-talk between interferon and retinoic acid pathways: From molecular biology to clinical applications
16. Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutation
17. Reduced retinoic acid-sensitivities of nuclear receptor co-repressor binding to PML- and PLZF-RARa underlie molecular pathogenesis and treatment of acute promyelocytic leukemia
18. Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL
19. A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression
20. Complete remission of t(11;17) acute promyelocytic leukemia induced by all-trans retinoic acid and granulocyte colony-stimulating factor
21. Sequential targeted therapy for relapsed acute promyelocytic leukemia with all-trans retinoic acid and anti-CD33 monoclonal antibody M195
22. Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia
23. Role of the histone deacetylase complex in acute promyelocytic leukaemia
24. Greater synergism of retinoic acid (RAR) agonists with vitamin D3 than that of retinoid X receptor (RXR) agonist with regard to growth inhibition and differentiation of monoblastic leukemia
25. Histone deacetylase inhibitors: Inducers of differentiation or apoptosis of transformed cells
26. Studies on the treatment of acute promyelocytic leukemia with arsenic trioxide, remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients
27. Initial clinical evaluation of "transcription therapy" for cancer: All-trans retinoic acid plus phenylbutyrate
28. Control of normal differentiation and the phenotypic reversion of malignancy in myeloid leukemia cells
29. Transcriptional activators direct histone acetyltransferase complexed to nucleosomes
30. Therapeutic targeting of transcription in acute promyelocytic leukemia use of an inhibitor of histone acetylase
31. Coactivator and corepressor complexes in nuclear receptor function